mutLBSgeneDB |
Gene summary for ALOX15B |
Gene summary |
Basic gene Info. | Gene symbol | ALOX15B |
Gene name | arachidonate 15-lipoxygenase, type B | |
Synonyms | 15-LOX-2 | |
Cytomap | UCSC genome browser: 17p13.1 | |
Type of gene | protein-coding | |
RefGenes | NM_001039130.1, NM_001039131.1,NM_001141.2, | |
Description | 15-LOX-B15S-lipoxygenasearachidonate 15-lipoxygenase 2arachidonate 15-lipoxygenase Barachidonate 15-lipoxygenase type IIarachidonate 15-lipoxygenase, second typearachidonate omega(6) lipoxygenaselinoleate 13-lipoxygenase 15-LOb | |
Modification date | 20141207 | |
dbXrefs | MIM : 603697 | |
HGNC : HGNC | ||
Ensembl : ENSG00000179593 | ||
HPRD : 04739 | ||
Vega : OTTHUMG00000108181 | ||
Protein | UniProt: O15296 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ALOX15B | |
BioGPS: 247 | ||
Pathway | NCI Pathway Interaction Database: ALOX15B | |
KEGG: ALOX15B | ||
REACTOME: ALOX15B | ||
Pathway Commons: ALOX15B | ||
Context | iHOP: ALOX15B | |
ligand binding site mutation search in PubMed: ALOX15B | ||
UCL Cancer Institute: ALOX15B | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0008285 | negative regulation of cell proliferation | 11839751 | GO:0019369 | arachidonic acid metabolic process | 10542053 | GO:0045786 | negative regulation of cell cycle | 11839751 | GO:0045926 | negative regulation of growth | 11839751 |
Top |
Ligand binding site mutations for ALOX15B |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | G17 | G17D | BRCA | 1 | N40,G42 | L41F | LUAD | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for ALOX15B |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | N40 | L41F | -1.3210453 | G42 | L41F | -1.3210453 | G17 | G17D | -0.46832631 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for ALOX15B from PDB |
Top |
Differential gene expression and gene-gene network for ALOX15B |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for ALOX15B |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for ALOX15B |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of ALOX15B go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | CA | CALCIUM(2+) | 4nre | A | G17 | CA | CALCIUM(2+) | 4nre | A | N40 G42 |
Top |
Conservation information for LBS of ALOX15B |
Multiple alignments for O15296 in multiple species |
LBS | AA sequence | # species | Species | A86 | PLAPDAWFCRW | 1 | Homo sapiens | A86 | SFRSDAWFCRW | 1 | Mus musculus | A86 | SFPPDAWYCRW | 1 | Rattus norvegicus | D39 | PLVPLDHLGKE | 2 | Mus musculus, Rattus norvegicus | D39 | PPLPLDNLGKE | 1 | Homo sapiens | D85 | GPLAPDAWFCR | 1 | Homo sapiens | D85 | MSFRSDAWFCR | 1 | Mus musculus | D85 | LSFPPDAWYCR | 1 | Rattus norvegicus | E44 | DHLGKEFSAGA | 2 | Mus musculus, Rattus norvegicus | E44 | DNLGKEFTAGA | 1 | Homo sapiens | G15 | TGEACGAGTWD | 2 | Mus musculus, Rattus norvegicus | G15 | TGEAFGAGTWD | 1 | Homo sapiens | G17 | EACGAGTWDKV | 2 | Mus musculus, Rattus norvegicus | G17 | EAFGAGTWDKV | 1 | Homo sapiens | G42 | PLDHLGKEFSA | 2 | Mus musculus, Rattus norvegicus | G42 | PLDNLGKEFTA | 1 | Homo sapiens | H373 | HEALTHLLHSH | 1 | Homo sapiens | H373 | HEAVTHLLHAH | 1 | Mus musculus | H373 | HEALTHLLHAH | 1 | Rattus norvegicus | H378 | HLLHAHLIPEV | 2 | Mus musculus, Rattus norvegicus | H378 | HLLHSHLLPEV | 1 | Homo sapiens | H553 | TCSAKHAAVSA | 2 | Homo sapiens, Rattus norvegicus | H553 | TCSAKHAAVSS | 1 | Mus musculus | I26 | KVSVSIVGTHG | 2 | Mus musculus, Rattus norvegicus | I26 | KVSVSIVGTRG | 1 | Homo sapiens | N40 | LVPLDHLGKEF | 2 | Mus musculus, Rattus norvegicus | N40 | PLPLDNLGKEF | 1 | Homo sapiens |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |